Genenta Science S.p.A. (GNTA) announced Tuesday that it's completely reinventing itself, shifting from developing cancer treatments to becoming what it calls a "next-generation strategic industrial consolidator" focused on acquiring defense and national security businesses. If that sounds like corporate speak for "we're doing something totally different now," you're not wrong.

From Lab Coats to Tactical Rifles

The transformation is about as dramatic as they come. Genenta plans to adopt the new name Saentra Forge S.p.A. and will target majority stakes in companies generating up to roughly 5 million euros (about $5.98 million) in EBITDA. The company's first move in this new direction involves ATC, a manufacturer of tactical rifles and special-forces weapon systems.

Genenta has signed a binding agreement to fund ATC with a total of 5.1 million euros. ATC is projected to hit approximately 4 million euros in revenue by 2026, with expectations to double its EBITDA in 2027. That's the kind of growth trajectory that apparently convinced Genenta's leadership this pivot makes sense.

The company's new governance structure revolves around the Praexidia Foundation, a private-law entity that's now a shareholder. The foundation, the company, and founder and CEO Pierluigi Paracchi have inked a shareholders' agreement that includes consultation rights on major corporate transactions and a renewable five-year lock-up period.

What Happens to the Biotech Business?

Genenta isn't completely abandoning its scientific roots, but it's definitely not prioritizing them. The company says it's hit important clinical milestones that position its cell therapy platform for partnerships with major pharmaceutical and biotech companies, which could accelerate development and boost strategic value.

To that end, Genenta has brought on DC Advisory as exclusive financial advisor to lead partnership discussions. The company wants to prioritize partnerships that expand the platform into broader applications, particularly hard-to-treat solid tumors and combination therapy strategies. It's also evaluating whether to continue developing Temferon as a monotherapy for glioblastoma multiforme (GBM).

The company will keep advancing its GBM trial but plans a capital-efficient strategy that relies heavily on partnerships. It won't be internally advancing the GU study or other clinical trials for now.

How the Market is Reacting

The stock showed some wild volatility following the announcement. Genenta Science shares currently trade 87.5% above their 20-day simple moving average of $1.39 and 10.6% above the 50-day SMA of $1.61, showing short-term strength.

But zoom out further and the picture looks rougher. The stock sits 10.6% below its 100-day SMA of $2.36 and 16.1% below its 200-day SMA of $3.10, suggesting longer-term struggles. Shares have dropped 68.29% over the past 12 months and are trading much closer to 52-week lows than highs.

Technical indicators paint a mixed picture. The RSI sits at 34.40, which is neutral territory, while the MACD is above its signal line, indicating bullish momentum. That combination suggests investors aren't quite sure what to make of this pivot yet.

Key technical levels to watch include resistance at $3 and support at $2.

Genenta expects to have approximately $33 million in cash, cash equivalents, and marketable securities as of December 31, 2025.

GNTA Price Action: Genenta Science shares surged more than 90% to reach $2.50 during premarket trading on Tuesday before dropping back to $1.38 at publication time.